TARSUS PHARMACEUTICALS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
TARSUS PHARMACEUTICALS, INC. (TARS) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $541.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2024-02-27
- TARSUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-06-30 was $44.00K, a 69.23% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-03-31 was $43.00K, a 258.33% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2020-12-31 was $56.00K, a 409.09% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2020-09-30 was $56.00K.
- TARSUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $541.00K, a 16.59% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $464.00K, a 57.82% increase from fiscal 2021.
- TARSUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $294.00K, a 96.00% increase from fiscal 2020.
- TARSUS PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $150.00K, a 305.41% increase from fiscal 2019.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | $541.00K 10-K · filed 2024-02-27 | |||
| 2022-12-31 | $464.00K 10-K · filed 2024-02-27 | |||
| 2021-12-31 | $294.00K 10-K · filed 2023-03-17 | |||
| 2021-06-30 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $87.00K 10-Q · filed 2021-08-05 | $143.00K derived: sum of 3 quarters · filed 2022-03-14 | $199.00K derived: sum of 4 quarters · filed 2022-03-14 |
| 2021-03-31 | $43.00K 10-Q · filed 2021-05-11 | $99.00K derived: sum of 2 quarters · filed 2022-03-14 | $155.00K derived: sum of 3 quarters · filed 2022-03-14 | $181.00K derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-12-31 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $112.00K derived: sum of 2 quarters · filed 2022-03-14 | $138.00K derived: sum of 3 quarters · filed 2022-03-14 | $150.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-25 | $82.00K derived: sum of 2 quarters · filed 2021-08-05 | $94.00K 10-Q · filed 2020-11-25 | $105.00K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $38.00K 10-Q · filed 2021-08-05 | $49.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $12.00K 10-Q · filed 2021-05-11 | $23.00K derived: sum of 2 quarters · filed 2021-05-11 | ||
| 2019-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $37.00K 10-K · filed 2021-03-31 | ||
| 2019-09-30 | $26.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |